A moment of pride! A co-first author in the best journal in medicine for a clinical trial that resulted in FDA approval in the USA and is changing how we treat acute myeloid leukemia #AMLsm. Congratulations to all the authors لحظة فخر! باحث أول مشارك في أفضل مجلة علمية في الطب لتجربة إكلينيكية أدت إلى موافقة إدارة الغذاء والدواء الأمريكية وتغير الطريقة التي نعالج بها اللوكيميا النخاعية الحادة.
MAJESTEC-9 trial at #ASCO26 : the message was strikingly simple: a couple of curves summarized it all. At the end, curves speak louder than words. @TheIACH@COMyCongress
Outstanding contribution led by Dr @IvanCivettini and the Humanitas team published in @NEJMEvidence which we at @YaleCancer were happy to be a part of it! Prognostic Score for Myelodysplastic Syndromes Based on Molecular Evolution | NEJM Evidence https://t.co/VtNUJVRoqh
🚨 The FDA approved oral decitabine and cedazuridine tablets with venetoclax for newly diagnosed AML in adults ≥75 years, or who have comorbidities that preclude the use of intensive induction chemotherapy.
https://t.co/z8MRDvataW
#leusm#AML#leukemia#oncology | @FDAOncology
Excited to announce a new paper out now in @CD_AACR on a unique CAR T cell platform that eliminates AML and B-ALL without harming vital endogenous immune cells or other normal human tissues:
https://t.co/IVb5KIYqMs
Stanford paid 35,000 people to quit Facebook and Instagram for 6 weeks
Depression dropped. Anxiety dropped. Happiness went up. Women under 25 on Instagram saw the biggest gains
That was 6 weeks. I'm going a full year.
Excited to join colleagues in NYC this July 11-12 for the 10th Annual Live Medical Crossfire®: Hematologic Malignancies. This year’s program will focus on navigating complex cases, new therapeutic approaches, and practical strategies you can take back to your clinic. Use code ZEIDAN for free HCP registration.
✅ Join us and register today: https://t.co/cd0rJfD2vk
@gotoper_
#MedicalCrossfire #gotoPER #Hematology #Oncology #CancerCare